Dexcom (DXCM) EBIT (2010 - 2026)

Dexcom (DXCM) has reported EBIT for 17 consecutive years, with $318.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 49.72% year-over-year to $318.3 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 65.76% increase from a year earlier, with the FY2025 full-year figure at $911.8 million, up 51.97% from the prior year.
• EBIT was $318.3 million for Q2 2026 at Dexcom, up from $255.3 million in the prior quarter.
• Over five years, EBIT peaked at $323.0 million in Q4 2025 and troughed at $41.3 million in Q1 2022.
• A 5-year average of $170.8 million and a median of $155.0 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 20800.0% in 2022 and decreased 26.03% in 2024, its largest moves.
• Over 5 years, EBIT stood at $125.4 million in 2022, then surged by 72.97% to $216.9 million in 2023, then dropped by 12.91% to $188.9 million in 2024, then soared by 70.99% to $323.0 million in 2025, then declined by 1.46% to $318.3 million in 2026.
• The last three EBIT figures came in at $318.3 million (Q2 2026), $255.3 million (Q1 2026), and $323.0 million (Q4 2025), per Business Quant data.